Clinical trial · Interventional
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
NCT06469307CI-TRIAL-00118127DIVERSErecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blood Cancer | Liquid Tumor | ALIAS | 0.90 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DIVERSE Review Process | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- DIVERSE Community Advisory Board (CAB)
- description
- Enrolled participants will complete: * Confidentiality agreement and demographic questionnaire * Online training and in-person or remote training with study team * Timely DIVERSE review of protocols * Audio recorded meeting (in-person, remote, or via phone call) with study team to present review findings * Semi-structured exit interview and/or focus group with study staff to provide feedback
- interventionNames
- Other: DIVERSE Review Process
- type
- OTHER
- label
- DIVERSE Investigators
- description
- Enrolled investigator participants will complete: * Brief Feedback Survey * Request DIVERSE reviews and complete request form * Acceptability of Intervention Measure questionnaire * Semi-structured exit interview and/or focus group with study staff to provide feedback
- interventionNames
- Other: DIVERSE Review Process
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
CAB Participant Inclusion Criteria: * Age 18 or older * English speaking * Ability to understand and willingness to provide oral consent * DFCI patient who are in remission from a blood cancer \>1 year will be preferred. CAB Participant Exclusion Criteria: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers \<18 years old) * Prisoners. * Unwilling/unable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1 * Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed. * Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews. Investigator Participant Inclusion Criteria: * Age 18 older * English Speaking * Site or Principal investigator * Not a member of the research team
References
Publications (0)
Data not yet available
No reference posted for this study.